[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Incyte Corp (INCY)

Incyte Corp (INCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Incyte Corp 1801 AUGUSTINE CUT-OFF WILMINGTON DE 19803 USA

www.incyte.com Employees: 2,844 P: 302-498-6700

Sector:

Medical

Description:

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2 inhibitor, approved in the United States for the treatment of patients with polycythemia vera ('PV'),who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and post-essential thrombocythemia MF. The drug is also approved in the United States for treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients aged 12 years or older.

Key Statistics

Overview:

Market Capitalization, $K 19,690,512
Enterprise Value, $K 16,592,692
Shares Outstanding, K 199,782
Float, K 164,221
% Float 82.20%
Short Interest, K 11,975
Short Float 5.99%
Days to Cover 9.79
Short Volume Ratio 0.75
% of Insider Shareholders 17.80%
% of Institutional Shareholders 96.97%

Financials:

Annual Sales, $ 5,141 M
Annual Net Income, $ 1,287 M
Last Quarter Sales, $ 1,273 M
Last Quarter Net Income, $ 303,330 K
EBIT, $ 1,611 M
EBITDA, $ 1,704 M

Growth:

1-Year Return 65.01%
3-Year Return 50.98%
5-Year Return 19.29%
5-Year Revenue Growth 92.79%
5-Year Earnings Growth 626.42%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 1.81 on 04/28/26
Next Earnings Date 08/04/26
Earnings Per Share ttm 6.45
EPS Growth vs. Prev Qtr -0.64%
EPS Growth vs. Prev Year 74.16%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 2-1 on 09/01/00

INCY Ratios

Ratio
Price/Earnings ttm 15.16
Price/Earnings forward 14.53
Price/Earnings to Growth 0.92
Return-on-Equity % 26.66%
Return-on-Assets % 19.77%
Profit Margin % 25.03%
Debt/Equity 0.00
Price/Sales 3.80
Price/Cash Flow 15.82
Price/Book 3.47
Book Value/Share 28.15
Interest Coverage 685.96
60-Month Beta 0.79
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.